Vamorolone

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) ranks 9th among top-performing biotech stocks in 2024, with Q3 2024 revenues of $128.7M, a 25.3% YoY increase. CPRX's success is driven by products like Firdapse and Agamree, with updated full-year revenue guidance of $475–$485M. Despite its performance, AI stocks are considered more promising for higher returns.

China’s NMPA approves Santhera’s Agamree for DMD in patients aged four and above, highlighting its safety benefits over standard corticosteroids. Agamree is already approved in the US, EU, and UK. Sperogenix Therapeutics will commercialize it in China under a $124m licence agreement, paying Santhera royalties and milestone payments.

Agamree (vamorolone) recommended by NICE for NHS use in treating Duchenne muscular dystrophy (DMD) in patients 4 and older. Expected to take effect within 90 days, Agamree aims to preserve muscle function and reduce side effects compared to traditional corticosteroids. Approved in the U.S., EU, U.K., and China, it offers an alternative treatment for DMD.

China's NMPA approves Santhera Pharmaceuticals' AGAMREE for treating Duchenne muscular dystrophy in patients aged four and above, marking the first approved treatment in the country for this indication. The approval follows the NMPA's acceptance of the new drug application in March 2024, highlighting AGAMREE's safety benefits over standard corticosteroids. Sperogenix holds exclusive rights to develop and commercialize AGAMREE in China.

NICE recommends Santhera's Agamree for DMD, available to 1,700 NHS patients aged 4+ after a price discount. Agamree, an alternative to corticosteroids, reduces side effects and maintains efficacy, offering benefits over current treatments.

NICE recommends AGAMREE® (vamorolone) for treating Duchenne muscular dystrophy (DMD) in patients 4 years and older in England, Wales, and Northern Ireland. Santhera works with NHS to ensure rapid patient access and pursues reimbursement in Scotland. AGAMREE is the first DMD treatment approved in the EU, US, and UK, offering an alternative to corticosteroids with reduced side effects.

Santhera Pharmaceuticals reports H1 2024 financial results, including CHF 14.1 million in revenue and a net loss of CHF 15.3 million. AGAMREE® (vamorolone) launched in Germany, Austria, and the U.S. for Duchenne muscular dystrophy (DMD), with strong market uptake. The drug received approval in the UK and NDA priority review in China. Santhera secured CHF 69 million in financing, expecting cash flow break-even by 2026.